{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T09:26:49Z","timestamp":1784366809460,"version":"3.55.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["069598\/Z\/02\/Z"],"award-info":[{"award-number":["069598\/Z\/02\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000864","name":"British HIV Association","doi-asserted-by":"publisher","award":["A1Algaratnam"],"award-info":[{"award-number":["A1Algaratnam"]}],"id":[{"id":"10.13039\/501100000864","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Virus Eradication"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jve.2024.100381","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T14:06:17Z","timestamp":1718287577000},"page":"100381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Impact of interrupting antiretroviral therapy started during primary HIV-1 infection on plasma neurofilament light chain protein, a marker of neuronal injury: The SPARTAC trial"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2256-423X","authenticated-orcid":false,"given":"Jasmini","family":"Alagaratnam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"St\u00f6hr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hamlyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kholoud","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Toombs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Heslegrave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Gissl\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Underwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Schechter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pontiano","family":"Kaleebu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Tambussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Kinloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Miro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony D.","family":"Kelleher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdel","family":"Babiker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Frater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Winston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Fidler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jve.2024.100381_bib1","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1097\/QAD.0000000000000243","article-title":"Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy","volume":"28","author":"May","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.jve.2024.100381_bib2","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.96.26.15109","article-title":"HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression","author":"Davey","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jve.2024.100381_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2012.08.010","article-title":"Redefining the viral reservoirs that prevent HIV-1 eradication","author":"Eisele","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.jve.2024.100381_bib4","article-title":"CD4+ count-guided interruption of antiretroviral treatment","author":"El-Sadr","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jve.2024.100381_bib5","series-title":"The Lancet HIV","article-title":"Recommendations for analytical antiretroviral treatment interruptions in HIV research trials\u2014report of a consensus meeting","author":"Julg","year":"2019"},{"key":"10.1016\/j.jve.2024.100381_bib6","doi-asserted-by":"crossref","DOI":"10.1097\/COH.0000000000000108","article-title":"Is the central nervous system a reservoir of HIV-1?","author":"Gray","year":"2014","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.jve.2024.100381_bib7","doi-asserted-by":"crossref","DOI":"10.1007\/s13365-014-0271-5","article-title":"HIV-1 transcriptional regulation in the central nervous system and implications for HIV cure research","author":"Churchill","year":"2015","journal-title":"J Neurovirol"},{"key":"10.1016\/j.jve.2024.100381_bib8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S2055-6640(20)30489-1","article-title":"CNS reservoirs for HIV: implications for eradication","volume":"1","author":"Hellmuth","year":"2015","journal-title":"J virus Erad"},{"key":"10.1016\/j.jve.2024.100381_bib9","doi-asserted-by":"crossref","DOI":"10.1007\/s13365-014-0287-x","article-title":"HIV-1 target cells in the CNS","author":"Joseph","year":"2015","journal-title":"J Neurovirol"},{"key":"10.1016\/j.jve.2024.100381_bib10","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/COH.0000000000000293","article-title":"Tissue reservoirs of HIV","volume":"11","author":"Wong","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.jve.2024.100381_bib11","doi-asserted-by":"crossref","DOI":"10.1093\/ve\/vew020","article-title":"Compartmentalized HIV rebound in the central nervous system after interruption of antiretroviral therapy","author":"Gianella","year":"2016","journal-title":"Virus Evol"},{"key":"10.1016\/j.jve.2024.100381_bib12","first-page":"260","article-title":"Rebound HIV-1 in cerebrospinal fluid after antiviral therapy interruption is mainly clonally amplified R5 T cell-tropic virus","author":"Kincer","year":"2023","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.jve.2024.100381_bib13","doi-asserted-by":"crossref","DOI":"10.1097\/QAD.0000000000000675","article-title":"The effect of short-course antiretroviral therapy initiated in primary HIV-1 infection on interleukin-6 and D-dimer levels","author":"Hamlyn","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.jve.2024.100381_bib14","article-title":"Neuroinflammation induces neurodegeneration","author":"Kempuraj","year":"2016","journal-title":"J Neurol Neurosurg spine"},{"key":"10.1016\/j.jve.2024.100381_bib15","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awg167","article-title":"Impaired fibrinolysis in multiple sclerosis: a role for tissue plasminogen activator inhibitors","author":"Gveric","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.jve.2024.100381_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-44198-z","article-title":"Systemic and intrathecal immune activation in association with cerebral and cognitive outcomes in paediatric HIV","author":"Blokhuis","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jve.2024.100381_bib17","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ebiom.2016.07.024","article-title":"HIV DNA set point is rapidly established in acute HIV infection and dramatically reduced by early ART","volume":"11","author":"Ananworanich","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jve.2024.100381_bib18","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jix662","article-title":"Anti-human immunodeficiency virus antibodies in the cerebrospinal fluid: evidence of early treatment impact on central nervous system reservoir?","author":"Burbelo","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jve.2024.100381_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiz031","article-title":"Antiretroviral treatment of acute HIV infection normalizes levels of cerebrospinal fluid markers of central nervous system (CNS) inflammation: a consequence of a reduced CNS reservoir?","author":"Gissl\u00e9n","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jve.2024.100381_bib20","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.03821","article-title":"HIV-1 DNA predicts disease progression and post-treatment virological control","volume":"3","author":"Williams","year":"2014","journal-title":"Elife"},{"key":"10.1016\/j.jve.2024.100381_bib21","doi-asserted-by":"crossref","DOI":"10.1097\/QAD.0000000000000734","article-title":"A low HIV-DNA level in peripheral blood mononuclear cells at antiretroviral treatment interruption predicts a higher probability of maintaining viral control","author":"Assoumou","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.jve.2024.100381_bib22","doi-asserted-by":"crossref","DOI":"10.7326\/M14-1027","article-title":"Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases","author":"Henrich","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jve.2024.100381_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofv037","article-title":"Activation of latent HIV by the histone deacetylase inhibitor panobinostat: a pilot study to assess effects on the CNS","volume":"2","author":"Rasmussen","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jve.2024.100381_bib24","doi-asserted-by":"crossref","DOI":"10.1097\/QAD.0000000000002264","article-title":"Perspective on potential impact of HIV central nervous system latency on eradication","author":"Chan","year":"2019","journal-title":"AIDS"},{"key":"10.1016\/j.jve.2024.100381_bib25","article-title":"Central nervous system safety during brief analytic treatment interruption of antiretroviral therapy within four HIV remission trials: an observational study in acutely treated people living with HIV","author":"Hellmuth","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jve.2024.100381_bib26","doi-asserted-by":"crossref","DOI":"10.1097\/QAD.0000000000002270","article-title":"Impact of analytical treatment interruption on the central nervous system in a simian-HIV model","volume":"33","author":"Hsu","year":"2019","journal-title":"AIDS"},{"key":"10.1016\/j.jve.2024.100381_bib27","doi-asserted-by":"crossref","DOI":"10.1097\/COH.0000000000000484","article-title":"Lessons learned from HIV antiretroviral treatment interruption trials","volume":"13","author":"Wen","year":"2018","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.jve.2024.100381_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","author":"Khalil","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.jve.2024.100381_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2018-320106","article-title":"Neurofilament light chain as a biomarker in neurological disorders","author":"Gaetani","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jve.2024.100381_bib30","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2019.1534","article-title":"Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis","author":"Bridel","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jve.2024.100381_bib31","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/14737159.2017.1341313","article-title":"Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls","volume":"17","author":"Yilmaz","year":"2017","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.jve.2024.100381_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116081","article-title":"Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection","author":"Peterson","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jve.2024.100381_bib33","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1007\/s00415-006-0481-8","article-title":"CSF neurofilament protein (NFL) - a marker of active HIV-related neurodegeneration","volume":"254","author":"Abdulle","year":"2007","journal-title":"J Neurol"},{"key":"10.1016\/j.jve.2024.100381_bib34","article-title":"Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study","author":"Gissl\u00e9n","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jve.2024.100381_bib35","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000007179","article-title":"Serum NFL discriminates Parkinson disease from atypical parkinsonisms","author":"Marques","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.jve.2024.100381_bib36","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2016.6117","article-title":"Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease","author":"Mattsson","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jve.2024.100381_bib37","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000004683","article-title":"Monitoring disease activity in multiple sclerosis using serum neurofilament light protein","author":"Novakova","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jve.2024.100381_bib38","doi-asserted-by":"crossref","DOI":"10.1007\/s13365-021-01026-3","article-title":"Correlation between cerebrospinal fluid and plasma neurofilament light protein in treated HIV infection: results from the COBRA study","volume":"28","author":"Alagaratnam","year":"2022","journal-title":"J Neurovirol"},{"key":"10.1016\/j.jve.2024.100381_bib39","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000271","article-title":"Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS","author":"Bergman","year":"2016","journal-title":"Neurol - Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.jve.2024.100381_bib40","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000004683","article-title":"Monitoring disease activity in multiple sclerosis using serum neurofilament light protein","author":"Novakova","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jve.2024.100381_bib41","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000003680","article-title":"Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder","author":"Hansson","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jve.2024.100381_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/acn3.325","article-title":"Neurofilament light chain: a biomarker for genetic frontotemporal dementia","author":"Meeter","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.jve.2024.100381_bib43","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2021-000143","article-title":"Correlation between CSF and blood neurofilament light chain protein: a systematic review and meta-analysis","volume":"3","author":"Alagaratnam","year":"2021","journal-title":"BMJ Neurol Open"},{"key":"10.1016\/j.jve.2024.100381_bib44","article-title":"Short-course antiretroviral therapy in primary HIV infection","author":"Fidler","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jve.2024.100381_bib45","series-title":"Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach","year":"2010"},{"key":"10.1016\/j.jve.2024.100381_bib46","series-title":"NF-Light","first-page":"1","author":"Sheet","year":"2017"},{"key":"10.1016\/j.jve.2024.100381_bib47","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/braincomms\/fcac174","article-title":"Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5-90 years","volume":"4","author":"Simr\u00e9n","year":"2022","journal-title":"Brain Commun"},{"key":"10.1016\/j.jve.2024.100381_bib48","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkaa003","article-title":"Evaluating predictive markers for viral rebound and safety assessment in blood and lumbar fluid during HIV-1 treatment interruption","author":"De Scheerder","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jve.2024.100381_bib49","article-title":"Potential for early antiretroviral therapy to reduce central nervous system HIV-1 persistence","author":"Spudich","year":"2019","journal-title":"AIDS"},{"key":"10.1016\/j.jve.2024.100381_bib50","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/infdis\/jiv296","article-title":"Absence of cerebrospinal fluid signs of neuronal injury before and after immediate antiretroviral therapy in acute HIV infection","volume":"212","author":"Peluso","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jve.2024.100381_bib51","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1093\/infdis\/jit088","article-title":"Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection","volume":"207","author":"Peluso","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jve.2024.100381_bib52","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1742-6405-2-6","article-title":"Cerebrospinal fluid signs of neuronal damage after antiretroviral treatment interruption in HIV-1 infection","volume":"2","author":"Gisslen","year":"2005","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.jve.2024.100381_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0043754","article-title":"Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection","author":"Hamlyn","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jve.2024.100381_bib54","doi-asserted-by":"crossref","DOI":"10.1097\/QAD.0000000000000155","article-title":"Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression","author":"Hamlyn","year":"2014","journal-title":"AIDS"}],"container-title":["Journal of Virus Eradication"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2055664024000189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2055664024000189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T15:46:05Z","timestamp":1720107965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2055664024000189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2055664024000189"],"URL":"https:\/\/doi.org\/10.1016\/j.jve.2024.100381","relation":{},"ISSN":["2055-6640"],"issn-type":[{"value":"2055-6640","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of interrupting antiretroviral therapy started during primary HIV-1 infection on plasma neurofilament light chain protein, a marker of neuronal injury: The SPARTAC trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Virus Eradication","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jve.2024.100381","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100381"}}